statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

M8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree (Viloxazine XR) in Latin America M8 Pharmaceuticals, an Acino company, signs an exclusive...

M8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree (Viloxazine XR) in Latin America

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Supernus Pharmaceuticals, Inc. - SUPN

Glancy Prongay & Murray LLP (GPM), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Supernus Pharmaceuticals, Inc. (Supernus or the...

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors

The Law Offices of Frank R. Cruz announces an investigation of Supernus Pharmaceuticals, Inc. (Supernus or the Company) (NASDAQ: SUPN) on behalf of investors concerning the Companys possible...

The Law Offices of Frank R. Cruz Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN  Get Free Report) VP Padmanabh P. Bhatt sold 14,491 shares of the companys stock in a transaction dated Thursday, March 21st. The stock was...

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Sells $511,677.21 in Stock

This is a signal that SUPN's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Supernus Pharmaceuticals (SUPN, $34.54) RSI Indicator left the overbought zone on March 22, 2024

Supernus Pharmaceuticals (SUPN, $35.17) RSI Indicator left the overbought zone on March 21, 2024

Supernus Pharmaceuticals (SUPN, $34.88) RSI Indicator left the overbought zone on March 20, 2024

Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005, and is headquartered in Rockville, MD.

Watchers	2,398
52-Wk Low	$21.99
52-Wk High	$38.08

Volume	461,434.00
52-Wk High	$38.08
52-Wk Low	$21.99

Period	Estimated	Reported	Surprise	Result
Q1'24	$0.26	--	--	N/A
Q4'23	$0.55	$0.88	59.50%	BEAT
Q3'23	$0.01	-$0.29	-5900.00%	MISSED
Q2'23	$0.21	-$0.02	-109.52%	MISSED
Q1'23	$0.31	$0.29	-5.43%	MISSED

SUPN Supernus Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals